10/05/2024
The gut microbiome plays an important part in many gastrointestinal conditions, including inflammatory bowel disease (IBD). Microbiome-based therapeutics has developed rapidly in the last decade, yet safety and regulatory hurdles remain.
A recent Series in The Lancet Gastroenterology & Hepatology explores the promise of artificial microbiome therapeutics, and the current and future therapies for treating IBD: https://hubs.li/Q02wGgB50
👇 Figure: Microbial consortia and therapeutic products modulate the microbiome and host physiology from paper 1.
